YS Biopharma Co., Ltd. (YS) has an overall financial health rating of B with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2024-05-24.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2024-05-24 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-23 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-22 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-21 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-20 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-17 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-16 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-15 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-14 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-13 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-05-09 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
